Artemis Hospitals
| India | Turchia | Austria | |
| Trapianto di midollo osseo allogenico da donatore non correlato | da $28,000 | da $80,000 | da $180,000 |
| Trapianto di midollo osseo allogenico da donatore consanguineo | da $20,500 | da $65,000 | da $150,000 |
| Trapianto di midollo osseo | da $15,000 | da $36,000 | da $140,000 |
| Trapianto autologo di midollo osseo | da $11,000 | da $31,500 | da $50,000 |
| Radioterapia per il cancro colorettale | da $3,200 | da $7,000 | da $12,000 |
Bookimed non aggiunge costi extra ai prezzi dei trattamenti di Linfoma non-Hodgkin. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica al tuo arrivo nel paese.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali nei trattamenti di Linfoma non-Hodgkin e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di trattamento per Linfoma non-Hodgkin.
Il medico è un ematologo-oncologo pediatrico con specializzazione nel trapianto di midollo osseo. Con un'ampia esperienza nel trattamento di pazienti pediatrici con disturbi del sangue e tumori, il medico ha contribuito significativamente ai progressi in questo campo. Il focus clinico include terapie innovative e cure centrate sul paziente, garantendo i migliori risultati per i giovani pazienti. Il medico è riconosciuto per la sua esperienza nella gestione di casi complessi e ha partecipato a numerosi studi clinici mirati a migliorare i protocolli di trattamento.<\/p>
Il medico è un ematologo-oncologo altamente esperto presso l'HCG Manavata Cancer Centre, Nashik, con oltre 13 anni di esperienza in leucemia, mieloma multiplo e trapianto di midollo osseo. <\/p>
Laureato con un MBBS presso il Grant Medical College e Sir JJ Hospital, il medico ha ulteriormente perseguito un MD in Patologia presso il Lokmanya Tilak Municipal Medical College, Sion, e Mumbai. <\/p>
Inoltre, il medico possiede un DM in Ematologia Clinica dal Medical College, Calcutta, e ha ricevuto premi per professionalità e duro lavoro, sottolineando la sua reputazione come specialista competente e qualificato.<\/p>
Advanced treatment for Non-Hodgkin lymphoma in India includes indigenous CAR T-cell therapy, advanced stem cell transplantation, and targeted immunotherapy. Facilities like Global Hospital Chennai and Apollo Hospital Indraprastha use PET-CT and IBM Watson technology to personalize treatment protocols for aggressive B-cell and T-cell lymphomas.
Bookimed Expert Insight: India oncology landscape shows a distinct advantage in hematology volume. Dr. Rahul Bhargava has performed over 1,000 transplants. This high procedural volume at JCI-accredited centers like Artemis Hospitals ensures clinical teams are exceptionally proficient in managing complex post-transplant recovery and immune responses.
Patient Consensus: Patients emphasize the importance of having a hematopathologist confirm the specific lymphoma subtype before starting treatment. They also note that integrated PET-CT planning is vital for monitoring how the tumor responds to early chemotherapy cycles.
Indian centers ensure safety through rigorous National Accreditation Board for Hospitals (NABH) and Joint Commission International (JCI) standards. These frameworks mandate strict protocols for infection control, surgical safety, and medication management. Specialized oncology hubs utilize advanced diagnostics like PET-CT and sentinel lymph node biopsy to maintain diagnostic precision.
Bookimed Expert Insight: Quality in India is often driven by massive patient volumes at major networks. For example, Manipal and Apollo each serve over 1,000,000 patients annually. This high frequency allows clinical teams to refine safety protocols for complex procedures. Some centers like HCG Manavata even integrate specialized IBM Watson technology to cross-reference cancer treatment plans against global clinical data.
Patient Consensus: Patients emphasize that safety is highest at large corporate hospitals with dedicated hematology teams. They recommend choosing centers that can manage all complications, including transfusions and infections, in-house without external transfers.
Recovery after Non-Hodgkin lymphoma treatment in India typically lasts 3 to 12 months. Most patients resume daily activities within 8 to 12 weeks following chemotherapy. Complex procedures like bone marrow transplants require a longer immune rebuilding phase of approximately 1 year.
Bookimed Expert Insight: Patient volume data highlights India as a global hub for complex hematology, with facilities like Apollo Hospital and Global Hospital Chennai each serving up to 2,000,000 patients annually. This massive scale allows specialists like Dr. Rahul Bhargava to perform over 1,000+ transplants. High procedural volume often correlates with more efficient recovery protocols, as these centers utilize advanced diagnostic tools like PET-CT and linear accelerators to monitor remission progress with 1 mm accuracy. Choosing a high-volume center may provide access to broader supportive care networks that accelerate the transition from hospital to home.
Good candidates for stem cell transplantation in India include patients with relapsed or refractory Non-Hodgkin lymphoma and those who responded well to salvage therapy. Eligibility requires stable heart and kidney function. Fit patients into their 70s are now routinely accepted at JCI-accredited centers.
Bookimed Expert Insight: While many assume age is a barrier, Indian specialists emphasize physiological age over chronological years. Dr. Rahul Bhargava has performed over 1,000 transplants, often for patients deemed high-risk elsewhere. Apollo Hospital Indraprastha operates as a massive transplant hub, serving over 1,000,000 international patients annually. Choosing high-volume centers is vital because their dedicated ICU backups better manage post-transplant recovery needs.
Patient Consensus: Patients note it's important to show a good response to chemotherapy before the transplant begins. They often worry about donor matches, but finding half-match options in India is increasingly common.
Indian oncology centers manage lymphoma side effects using protocol-driven supportive care and advanced medical monitoring. Facilities integrate specialized antiemetics, growth factors, and targeted analgesics into therapy plans. Treatment stays safe through multi-disciplinary teams and formal integration of traditional AYUSH systems to ease fatigue.
Bookimed Expert Insight: Indian centers excel at managing side effects through high-capacity infrastructure that prioritizes outpatient care. Manipal Hospitals and Apollo Hospitals serve over 1,000,000 patients annually. This volume creates a standardized response to complications. Many centers use diagnostic tech like PET-CT to monitor toxicity early. For example, Manipal Goa Hospital uses IBM Watson to select protocols that minimize adverse reactions based on global patient data.
Patient Consensus: Patients emphasize the need to report fever or low counts immediately for urgent care. They note that family members often lead the effort in tracking symptoms and managing home hydration routines.
Major Indian centers for Non-Hodgkin lymphoma treatment are concentrated in Delhi-NCR, Mumbai, Chennai, and Bengaluru. These regional hubs house JCI and NABH-accredited facilities. They provide advanced care like autologous bone marrow transplants, targeted immunotherapy, and specialized pediatric hemato-oncology services for complex cases.
Bookimed Expert Insight: While many patients focus on Delhi or Mumbai, Bengaluru emerges as a strong contender for complex cases due to high-volume expertise. Manipal Hospitals alone serves 2,000,000 patients annually across its network. This massive patient volume often correlates with higher proficiency in managing rare lymphoma subtypes. Our data shows that centers in southern India frequently offer a higher bed-to-doctor ratio than those in Delhi.
Patient Consensus: Patients note it is vital to choose a center in a city where they can easily manage long-term follow-ups. They emphasize getting a second pathology opinion and selecting high-volume clinics that specialize specifically in blood cancers for better results.
Non-Hodgkin's lymphoma is highly curable in India, particularly aggressive subtypes like diffuse large B-cell lymphoma. Doctors use international R-CHOP protocols and CAR T-cell therapy. Major JCI-accredited hospitals in Bengaluru and Delhi report complete remission rates reaching 70%. These rates apply to standard first-line treatments.
Bookimed Expert Insight: Indian oncology centres often offer high-density diagnostic tech. This includes 4D radiotherapy and Alpha-knife radiosurgery, which isn't standard in every region. For example, HCG Manavata Cancer Centre has performed over 65,000 cancer surgeries. This high volume allows surgeons to manage complex relapsed cases. They use both autologous and allogeneic transplants with high precision.
Patient Consensus: Patients note that aggressive B-cell lymphomas often reach complete remission in India. They recommend confirming the exact subtype early. Treatments for mantle cell lymphoma focus on long-term management rather than a definitive cure.
Top Indian hospitals for Non-Hodgkin's lymphoma include Manipal Hospital, Apollo Hospital Indraprastha, and Artemis Hospitals. These centres hold JCI and NABH accreditations. These centres offer chemotherapy, immunotherapy, and bone marrow transplants. Specialist haematologists provide haploidentical stem cell transplants and CAR T-cell therapy for complex cases.
Bookimed Expert Insight: Many Australian patients look to major metros. However, HCG Manavata in Nashik represents a significant data standout. It is Maharashtra's first NABH-accredited cancer hospital and houses a US-FDA audited research institute. This combines high volume and international oversight. Patients therefore receive protocols validated to global clinical standards.
Patient Consensus: Patients note that confirming the specific lymphoma subtype before travel speeds up start times. Experience in India shows that government-funded hubs are affordable. However, private hospitals in Bengaluru and Delhi offer quicker admission for Australians.
India reports high survival rates for specific Non-Hodgkin lymphoma cases. Stage 4 classic Hodgkin lymphoma sees success in 87–90% of patients. Early diagnosis and cellular therapies in JCI-accredited centres significantly improve outcomes. These results often match global standards for aggressive subtypes.
Bookimed Expert Insight: Quality of outcome in India is often tied to facility volume and research. HCG Manavata Cancer Centre has performed 65,000+ surgeries and 65+ bone marrow transplants. Centres with US-FDA audited research units often provide more precise survival projections. Patients should focus on hospitals with dedicated paediatric or adult haematology-oncology wings. This can lead to better recovery prospects.
Patient Consensus: Patients emphasise getting a precise subtype diagnosis. They note that seeking second opinions at major Indian hospitals helps. This aligns local treatment plans with international standards. Many suggest using personal coordinators. These help manage the logistics of long-term care in Delhi or Bengaluru.
India provides immediate access to Non-Hodgkin's lymphoma treatments, including CAR T-cell therapy and allogeneic bone marrow transplants. JCI-accredited centres such as Artemis Hospitals and Manipal Hospitals offer complex diagnostics. They use PET-CT and IBM Watson for Oncology. This ensures high clinical accuracy. Patients also avoid the waiting lists sometimes found in public systems.
Bookimed Expert Insight: Many centres focus on chemotherapy. However, Indian clinics like Dr Rela Institute and HCG Manavata Cancer Centre lead in high-precision radiotherapy and bone marrow transplants. HCG Manavata is Maharashtra's first NABH-accredited cancer hospital. It completed over 65 bone marrow transplants in just 2.5 years. Patients seeking these specific, intensive procedures may find India's high-volume experience leads to smoother clinical pathways.
Patient Consensus: Patients note India is a strong choice when they need treatment to start quickly. They highlight the value of having personal coordinators, interpreters, and tailored meals. These are included in their stay.
Diagnosis in India follows a systematic path involving haematologist consultations, lymph node biopsies, and imaging. Specialists use immunophenotyping to identify specific lymphocyte markers. This provides precise classification of the lymphoma subtype. Major Indian medical centres often complete these assessments within a few days.
Bookimed Expert Insight: Indian diagnostic labs like those at Apollo Hospital Indraprastha are among the region's most modern. While some patients face delays elsewhere, leading private hubs often coordinate biopsy and IHC results simultaneously. This efficiency is vital. Accurate subtype identification directly dictates whether a patient needs chemotherapy or immunotherapy.
Patient Consensus: Patients note that initial symptoms like lumps are often mistaken for infections or tuberculosis. This is common in India. Confirming the diagnosis usually requires more than basic ultrasounds. It needs a definitive tissue biopsy and IHC testing.